Alphs L, Benson C, Cheshire-Kinney K, Lindenmayer J-P, Mao L, Rodriguez SC, Starr HL (2015). Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia. Journal of Clinical Psychiatry
Alphs L, Bossie CA, Sliwa JK, Ma Y-W, Turner N (2011). Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial. Annals of General Psychiatry
Ascher-Svanum H, Peng X, Faries D, Montgomery W, Haddad PM (2009). Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients. BMC Psychiatry
Attard A, Olofinjana O, Cornelius V, Curtis V, Taylor D (2014). Paliperidone palmitate long-acting injection--prospective year-long follow-up of use in clinical practice. Acta Psychiatrica Scandinavica
Barnes TRE (2005). Why indeed?: Invited commentary on… Why aren't depot antipsychotics prescribed more often and what can be done about it?
Advances in Psychiatric Treatment
Berwaerts J, Liu Y, Gopal S, Nuamah I, Xu H, Savitz A, Coppola D, Schotte A, Remmerie B, Maruta N, Hough DW (2015). Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia. JAMA Psychiatry
Bosanac P, Castle D (2015). Why are long-acting injectable antipsychotics still underused?. Advances in Psychiatric Treatment
Brissos S, Veguilla MR, Taylor D, Balanzá-Martinez V (2014). The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Therapeutic Advances in Psychopharmacology
Coppola D, Liu Y, Gopal S, Remmerie B, Samtani MN, Hough DW, Nuamah I, Sulaiman A, Pandina G (2012). A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia. BMC Psychiatry
Decuypere F, Sermon J, Geerts P, Denee TR, De Vos C, Malfait B, Lamotte M, Mulder CL (2017). Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: a retrospective database study. PLoS ONE
Fleischhacker WW, Gopal S, Lane R, Gassmann-Mayer C, Lim P, Hough D, Remmerie B, Eerdekens M (2012). A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. International Journal of Neuropsychopharmacology
Furukawa TA, Levine SZ, Tanaka S, Goldberg Y, Samara M, Davis JM, Cipriani A, Leucht S (2015). Initial severity of schizophrenia and efficacy of antipsychotics. JAMA Psychiatry
Haddad PM, Kishimoto T, Correll CU, Kane JM (2015). Ambiguous findings concerning potential advantages of depot antipsychotics. Current Opinion in Psychiatry
Health and Social Care Information Centre (2016). Prescription Cost Analysis, England - 2015, NHS Digital.
Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M (2010). Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophrenia Research
Johnson DAW (2009).
Historical perspective on antipsychotic long-acting injections
. British Journal of Psychiatry
Kirson NY, Weiden PJ, Yermakov S, Huang W, Samuelson T, Offord SJ, Greenberg PE, Wong BJO (2013). Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. Journal of Clinical Psychiatry
Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU (2013).
Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies
. Journal of Clinical Psychiatry
Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, Borenstein M, Kane JM, Correll CU (2014). Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophrenia Bulletin
Kozma CM, Slaton T, Dirani R, Fastenau J, Gopal S, Hough D (2011). Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE). Current Medical Research and Opinion
Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y, Eerdekens M (2010). Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. The International Journal of Neuropsychopharmacology
Kramer M, Simpson G, Maciulis V, Kushner S, Vijapurkar U, Lim P, Eerdekens M (2007). Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia. Journal of Clinical Psychopharmacology
Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S (2011). Oral versus depot antipsychotic drugs for schizophrenia-A critical systematic review and meta-analysis of randomised long-term trials. Schizophrenia Research
Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. The Lancet
Li H, Rui Q, Ning X, Xu H, Gu N (2011). A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry
Marcus SC, Zummo J, Pettit AR, Stoddard J, Doshi JA (2015). Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. Journal of Managed Care & Specialty Pharmacy
Markowitz M, Fu D-J, Levitan B, Gopal S, Turkoz I, Alphs L (2013). Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies. Annals of General Psychiatry
McCrone P, Dhanasiri S, Patel A, Knapp M, Lawton-Smith S (2008). Paying the Price: The Cost of Mental Health Care in England to 2026. The King's Fund.
McEvoy JP, Byerly M, Hamer RM, Dominik R, Swartz MS, Rosenheck RA, Ray N, Lamberti JS, Buckley PF, Wilkins TM, Stroup TS (2014). Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia. Journal of the American Medical Association
Mehnert A, Nicholl D, Pudas H, Martin M, McGuire A (2012). Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. Journal of Medical Economics
Muser E, Kozma CM, Benson CJ, Mao L, Starr HL, Alphs L, Fastenau J (2015). Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement. Journal of Medical Economics
Naber D, Hansen K, Forray C, Baker RA, Sapin C, Beillat M, Peters-Strickland T, Nylander AG, Hertel P, Andersen HS, Eramo A, Loze JY, Potkin SG (2015). Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophrenia Research
Pandina G, Lane R, Gopal S, Gassmann-Mayer C, Hough D, Remmerie B, Simpson G (2011). A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Neuro-Psychopharmacology & Biological Psychiatry
Patel R, Chesney E, Cullen AE, Tulloch AD, Broadbent M, Stewart R, McGuire P (2016a). Clinical outcomes and mortality associated with weekend admission to psychiatric hospital. British Journal of Psychiatry
Patel R, Jayatilleke N, Broadbent M, Chang C-K, Foskett N, Gorrell G, Hayes RD, Jackson R, Johnston C, Shetty H, Roberts A, McGuire P, Stewart R (2015a). Negative symptoms in schizophrenia: a study in a large clinical sample of patients using a novel automated method. BMJ Open
5, 1–9, e007619.
Patel R, Lloyd T, Jackson R, Ball M, Shetty H, Broadbent M, Geddes JR, Stewart R, McGuire P, Taylor M (2015b). Mood instability is a common feature of mental health disorders and is associated with poor clinical outcomes. BMJ Open
5, 1–9, e007504.
Patel R, Reiss P, Shetty H, Broadbent M, Stewart R, McGuire P, Taylor M (2015c). Do antidepressants increase the risk of mania and bipolar disorder in people with depression? A retrospective electronic case register cohort study. BMJ Open
5, 1–6, e008341.
Patel R, Shetty H, Jackson R, Broadbent M, Stewart R, Boydell J, McGuire P, Taylor M (2015d). Delays before diagnosis and initiation of treatment in patients presenting to mental health services with bipolar disorder. PLoS ONE
10, 1–17, e0126530.
Patel R, Wilson R, Jackson R, Ball M, Shetty H, Broadbent M, Stewart R, McGuire P, Bhattacharyya S (2016b). Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study. BMJ Open
6, 1–9, e009888.
Pinto R, Ashworth M, Seed P, Rowlands G, Schofield P, Jones R (2010). Differences in the primary care management of patients with psychosis from two ethnic groups: a population-based cross-sectional study. Family Practice
Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Janik A, Schotte A, Hough D, Fleischhacker WW (2016). Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study. International Journal of Neuropsychopharmacology
Schreiner A, Aadamsoo K, Altamura AC, Franco M, Gorwood P, Neznanov NG, Schronen J, Ucok A, Zink M, Janik A, Cherubin P, Lahaye M, Hargarter L (2015). Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophrenia Research
Taylor D, Olofinjana O (2014). Long-acting paliperidone palmitate – interim results of an observational study of its effect on hospitalization. International Clinical Psychopharmacology
Taylor DM, Fischetti C, Sparshatt A, Thomas A, Bishara D, Cornelius V (2009). Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice. Journal of Clinical Psychiatry
Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P (2011). A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. American Journal of Psychiatry
Voss EA, Ryan PB, Stang PE, Hough D, Alphs L (2015). Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics. International Clinical Psychopharmacology
Zeidler J, Mahlich J, Greiner W, Heres S (2013). Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany. Applied Health Economics and Health Policy